NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension

NCT01191008

CompletedN/A

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions: Glaucoma, Ocular Hypertension

Interventions: Latanoprost-timolol maleate fixed combination ophthalmic solution

The objective of this Investigation is to evaluate the safety and efficacy of long-term treatment with Xalacom in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Xalacom will be monitored during the survey period, and whether an additional treatment outcome investigation and/or a post-marketing clinical study is required in the future will be determined.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients need to be administered Xalacom® in order to be enrolled in the surveillance.

Exclusion Criteria:

* Patients not administered Xalacom®.